Biomedical Engineering Reference
In-Depth Information
154. Di Fiore, P.P.,
et al.
, erbB-2 is a potent oncogene when overexpressed in
NIH/3T3 cells.
Science
, 1987.
237
(4811): 178-182.
155. Segatto, O.,
et al.
, Different structural alterations upregulate
in vitro
tyrosine kinase activity and transforming potency of the erbB-2 gene.
Mol Cell Biol
, 1988.
8
(12): 5570-5574.
156. Langton, B.C.,
, An antigen immunologically related to the external
domain of gp185 is shed from nude mouse tumors overexpressing the
c-erbB-2 (HER-2/neu) oncogene.
et al.
Cancer Res
, 1991.
51
(10): 2593-
2598.
157. Baselga, J.,
, Phase II study of weekly intravenous recombinant
humanized anti-p185HER2 monoclonal antibody in patients with
HER2/neu-overexpressing metastatic breast cancer.
et al.
J Clin Oncol
, 1996.
(3): 737-744.
158. Leitzel, K.,
14
, Elevated serum c-erbB-2 antigen levels and decreased
response to hormone therapy of breast cancer.
et al.
J Clin Oncol
, 1995.
(5): 1129-1135.
159. Yamauchi, H.,
13
, Prediction of response to antiestrogen therapy in
advanced breast cancer patients by pretreatment circulating levels of
extracellular domain of the HER-2/c-neu protein.
et al.
J Clin Oncol
, 1997.
(7): 2518-2525.
160. Brodowicz, T.,
15
, Soluble HER-2/neu neutralizes biologic effects of
anti-HER-2/neu antibody on breast cancer cells
et al.
in vitro.
Int J Cancer
,
(6): 875-879.
161. Harris, L.,
1997.
73
, American society of clinical oncology 2007 update of
recommendations for the use of tumor markers in breast cancer.
et al.
J Clin
(33): 5287-5312.
162. Leyland-Jones, B., and B.R. Smith, Serum HER2 testing in patients with
HER2-positive breast cancer: the death knell tolls.
Oncol
, 2007.
25
Lancet Oncol
, 2011.
(3): 286-295.
163. Finn, R.S.,
12
, Prognostic and predictive value of HER2 extracellular
domain in metastatic breast cancer treated with lapatinib and
paclitaxel in a randomized phase III study.
et al.
J Clin Oncol
, 2009.
27
(33):
5552-5558.
164. Gravalos, C.,
, Phase II study of trastuzumab and cisplatin as
first-line therapy in patients with HER2-positive advanced gastric or
gastroesophageal junction cancer.
et al.
Clin Transl Oncol
, 2011.
13
(3): 179-
184.
165. Bang, Y.J.,
, Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
et al.
